---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-032116"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:40:04.208587+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte announces $20M registered direct offering of 25M shares at $0.80/share

## Summary
- Gross proceeds of $20M from 25M shares at $0.80; net proceeds ~$18.4M after fees.
- Offering led by a new life science dedicated investor and a long-only mutual fund.
- Net proceeds to fund Symvess commercialization, hemodialysis Phase 3 read-out, and pipeline.
- Expected to close March 20, 2026, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001104659-26-032116
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/tm269106d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-032116
- JSON: https://secwatch.observer/filing/0001104659-26-032116.json
- Plain text: https://secwatch.observer/filing/0001104659-26-032116.txt

## Key facts
- Material Agreements
  Humacyte, Inc. entered into Placement Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-03-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
  - Effective: 2026-03-19
  source text: On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement agent (the “Placement Agent”), in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm
- Material Agreements
  Humacyte, Inc. entered into Purchase Agreements with certain investors valued at 25,000,000 shares ... at a price of $0.80 per share (effective 2026-03-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: 25,000,000 shares ... at a price of $0.80 per share
  - Effective: 2026-03-19
  source text: On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000110465926032116/0001104659-26-032116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.